X

Stay Connected

Sign Up for Updates

 
We are creating a place where we can share ideas, provide the perspective of America's biopharmaceutical companies and, most importantly, listen to you.

Understanding Long COVID-19

By Richard Moscicki, M.D.  |    September 29, 2021
The Centers for Disease Control and Prevention (CDC) defines long COVID as health problems lasting four or more weeks after first getting infected with the novel coronavirus, impacting as many as ...   Read More

Biosimilar User Fee Act (III) Performance Goals Letter will help increase options for patients and promote competition

By Richard Moscicki, M.D.  |    September 28, 2021
Last week, the U.S. Food and Drug Administration (FDA) released the Performance Goals Letter for the Biosimilar User Fee Act (BsUFA) III.   Read More

Upcoming graduate student summit will showcase pathways to success within the biopharmaceutical industry

By Stephen J. Ubl  |    September 28, 2021
I am excited to join with Dr. Michael L. Lomax, President & CEO, UNCF; Dr. James Gillespie, President & Co-Founder, Center for Healthcare Innovation (CHI); and Dr. Chad Womack, Co-Founder and...   Read More

Meeting Tomorrow: Looking ahead to PDUFA VII

By Andrew Powaleny  |    September 27, 2021
Tomorrow, PhRMA will participate at the U.S. Food and Drug Administration’s (FDA) public meeting on the reauthorization of the Prescription Drug User Fee Act (PDUFA VII).   Read More

Guest Series: PhRMA talks racial and health equity with Lauren Powell, VP US Health Equity and Community Wellness, Takeda

By Courtney Christian  |    September 27, 2021
Our industry has committed itself to making our workplaces trusting places to have complex, and sometimes difficult, conversations about diversity and inclusion.   Read More

Industry leaders discuss the impact of the drug pricing debate

By Brian Newell  |    September 23, 2021
This month, PhRMA hosted a media briefing with leaders within the biopharmaceutical industry to discuss the dangers of current proposals on government price setting, while also sharing alternative...   Read More

A global focus on ending the COVID-19 pandemic

By Stephen J. Ubl  |    September 22, 2021
Today, President Biden convened global leaders to confront the challenges around ending this pandemic. We stand with the president, all governments, organizations and sectors in a shared...   Read More

Five reasons tying VA prices to Medicare Part D misses the mark

By Nicole Longo  |    September 22, 2021
Some members of Congress are considering a government “negotiation” plan that would tie medicine prices in Medicare to those in the U.S. Department of Veterans Affairs (VA). This misguided...   Read More

PhRMA awards $150,000 to community-based projects aimed at tackling inequities in access to COVID-19 testing, vaccines and therapeutics

By Jackie McRae  |    September 21, 2021
The COVID-19 pandemic has widened health disparities, including the gap in average life expectancy and outcomes for many chronic diseases. These inequities in health status and outcomes among...   Read More

PhRMA releases 2021 industry profile

By Gabby Migliara  |    September 20, 2021
Today, PhRMA released its 2021 Biopharmaceutical Industry Profile, a resource that highlights the latest from the industry on innovation, access and affordability. The Profile has told the story...   Read More

Addressing data challenges to improve health equity

By Emily Donaldson  |    September 17, 2021
The COVID-19 pandemic has shed light on the ways that systemic racism pervades nearly every facet of life – especially within our health care system. The biopharmaceutical industry is dedicated to...   Read More

America’s biopharmaceutical companies to Congress: Government “negotiation” is the wrong approach

By Stephen J. Ubl  |    September 15, 2021
Today, PhRMA member companies made public an open letter to Capitol Hill to encourage Congress to abandon old partisan ideas on drug pricing and instead pursue policies that actually address what...   Read More

A year and a half later: The biopharmaceutical industry remains committed to beating COVID-19

By Joseph Havey  |    September 8, 2021
Since the start of the pandemic, America’s biopharmaceutical companies have worked around the clock to research, develop and manufacture treatments and vaccines to fight COVID-19. Already, we’ve...   Read More

Patients and innovators lose if the government pursues ‘march-in’

By Megan Van Etten  |    September 7, 2021
The Biden Administration this summer issued an executive order that seems to endorse the use of “march-in” – when the government seizes patent rights from an innovator to let competitors use that...   Read More

The impact of monoclonal antibodies and COVID-19 recovery

By Andrew Powaleny  |    September 2, 2021
As the United States and world continue to fight the COVID-19 pandemic, America’s biopharmaceutical research companies continue to do our part in fighting this deadly virus. Decades of scientific...   Read More

Search the Catalyst

View Posts by Topic

see all

View Posts by Contributor

View Posts by Date

see all

Subscribe to Email Updates